Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jin H., Liu, Yingting, Lemmon, Mark A., Radhakrishnan, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2012
Materias:
Accelerated Publication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507260/
https://www.ncbi.nlm.nih.gov/pubmed/23101586
http://dx.doi.org/10.1042/BJ20121513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507260/
https://www.ncbi.nlm.nih.gov/pubmed/23101586
http://dx.doi.org/10.1042/BJ20121513

Ejemplares similares